News

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

The latest news for pharma industry insiders.

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare.

Analyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.

FDA to review one-year results for Susvimo showing non-inferior visual acuity gains in diabetic macular edema and in the Diabetic Retinopathy Severity Scale for Diabetic Retinopathy.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, dives into efficiencies presented by at-home diagnostic tests.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, discusses findings of a new physician survey that the company conducted.

The agreement revolves around providing and maintaining supply chain transparency.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.

The 50,000 square-foot facility has the ability to handle various batch sizes and dosage forms.

The clinical supply facility undergoes a $25 million expansion, welcoming 32,000 more square feet of temperature-controlled storage.

A study explores the cost-effectiveness of combining methotrexate with various drugs as a way to combat failed methotrexate monotherapy.

The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.

Why they are a game changer, and ways to a adapt to a new era of state privacy regulations.

The acquisition in the ophthalmology space features a $1.3 billon cash payment, with the potential for an additional $1.7 billion if various milestones are met.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

New production line represents Rentschler Biopharma SE’s biggest investment in its 150-year history.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth's founder and CEO, offers his thoughts surrounding the lack of supply.

Why these programs require a hybrid approach that combines technology and human connection.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

Double-digit, year-on-year growth is now on a six-month streak.

An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.

The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.